Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Changchun Reinovax Biologics
Changchun, Jilin, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Changchun Reinovax Biologics (as part of Reinovax) is advancing a 24-valent pneumococcal conjugate vaccine for pneumonia prevention. The vaccine is in phase 2 trials in China for pneumococcal infections across adults, elderly, children, and adolescents. Phase 1 has been completed successfully in both adults and pediatric populations[2][5][1].
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineConjugate vaccinePolysaccharideBiologic
- Industry
- Biotech
02
Partnerships
Collaborates with national and international universities and research institutions[1][3].
Beyond the preview
Go deeper on Changchun Reinovax Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Changchun Reinovax Biologics.